Shopping Cart 0
Cart Subtotal
USD 0

Genentech Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including bio-oncology, immunology, ophthalmology, metabolism, primary care, neurology, virology, hematology and specialty care. It has pipeline candidates in oncology, immunology, neuroscience, metabolism, infectious disease and ophthalmology. The company has research and manufacturing facilities in Vacaville, South San Francisco and Oceanside, California. Genentech is headquartered in South San Francisco, California, the US.

Genentech Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13

Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Genentech Inc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17

Partnerships 18

Affimed to Enter into Co-Development Agreement with Genentech 18

Microbiotica Enters into Collaboration Agreement with Genentech 19

Tesaro Enters into Collaboration Agreement with Genentech 20

Lodo Therapeutics Enters into Agreement with Genentech 21

Tesaro Enters into Partnership with Genentech 22

Forty Seven Enters into Agreement with Genentech 23

Syndax Pharma Enters into Agreement with Genentech 24

DiCE Molecules Enters into Research Agreement with Genentech 25

Biothera Pharma Enters into Collaboration Agreement with Genentech 26

Epizyme Enters into Agreement with Genentech 27

Inovio Pharma Enters into Agreement with Genentech 28

Amunix Operating Enters into R&D Agreement with Genentech 29

BioNTech Enters into Agreement with Genentech 30

Gradalis Enters into Agreement with Genentech 31

G1 Therapeutics Enters into Agreement with Genentech 32

Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 33

Charles River Laboratories International Extends Agreement with Genentech 34

BioLineRx Enters into Agreement with Genentech 35

Epizyme Enters into Agreement with Genentech 36

Astex Pharma Enters into Agreement with Genentech 37

Clovis Oncology Enters into Agreement with Genentech 38

Janssen Research & Development Enters into Agreement with Genentech 39

Kite Pharma Enters into Agreement with Genentech 40

PeptiDream Enters into Agreement with Genentech 41

Corvus Pharma Expands its Agreement with Genentech 42

Immune Design Enters into Clinical Trial Collaboration with Genentech 43

WaferGen Bio-systems Enters into Research Agreement with Genentech 44

23andMe Partners with Genentech 45

Genentech Enters into Research Agreement with NewLink Genetics 46

Ascendis Pharma Enters Into Collaboration Agreement with Genentech 47

RQx Pharma Enters Into Drug Discovery Agreement With Genentech 48

Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 49

Constellation Pharma Enters into Co-Development Agreement With Genentech 50

Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 51

Licensing Agreements 52

Genentech Enters into Licensing Agreement with Kineta Chronic Pain 52

Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 53

Mylan Enters into Licensing Agreement with Genentech and Roche 55

Genentech Enters into Licensing Agreement with Novimmune 56

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 57

Genentech to Enter into Licensing Agreement with Hanmi Pharma 58

Denali Therapeutics Enters Into Licensing Agreement With Genentech 59

Genentech Enters into Licensing Agreement with Nimbus Therapeutics 60

Genentech Expands Licensing Agreement with Arvinas 61

Genentech Enters into Licensing Agreement with Almac Discovery 62

Phylogica Extends Licensing Agreement with Genentech 63

Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 64

Coherus BioSciences Enters into Licensing Agreement with Genentech 66

Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 67

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 68

Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 69

Genentech Enters into Licensing Agreement with Carmot Therapeutics 70

Afraxis Enters Into Licensing Agreement With Genentech 71

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 72

Acquisition 74

Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 74

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 75

Genentech Inc-Key Competitors 76

Genentech Inc-Key Employees 77

Genentech Inc-Locations And Subsidiaries 78

Head Office 78

Other Locations & Subsidiaries 78

Recent Developments 79

Legal and Regulatory 79

Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 79

Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 80

Government and Public Interest 81

May 14, 2018: Pivotal Study Validates Real-World Mortality Endpoint for Oncology Research 81

Jun 29, 2017: Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury 82

Product News 83

Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 83

06/15/2017: NICE reverses provisional decision and recommends Kadcyla (trastuzumab emtansine) for HER2-positive advanced breast cancer in England 85

06/12/2017: T-DM1 in HER2 Overexpressing, Amplified or Mutated Metastatic NSCLC 86

Product Approvals 88

Jun 15, 2017: Kadcyla new deal for breast cancer patients given green light in final draft guidance 88

Apr 10, 2017: Roche's Kadcyla accepted for use in NHS Scotland 89

Clinical Trials 90

Apr 15, 2018: Genentech to Present Data on Investigational Anti-amyloid beta Antibodie Crenezumab 90

Dec 10, 2017: Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma 91

Nov 30, 2017: Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease 93

Nov 01, 2017: Data To Be Presented On Polatuzumab Vedotin At ASH 2017 Annual Meeting 94

Oct 24, 2017: AC Immune to Provide Scientific Update on Crenezumab at CTAD Conference 95

May 17, 2017: Data from Clinical Study of NewLink Genetics' Navoximod to Be Presented at ASCO 2017 96

Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 97

Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab 98

Other Significant Developments 99

Feb 05, 2018: Inside Rx Provides Savings on Influenza Medications 99

Appendix 100

Methodology 100

About GlobalData 100

Contact Us 100

Disclaimer 100


List Of Figure

List of Figures

Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Genentech Inc, Pharmaceuticals & Healthcare, Key Facts 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Genentech Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13

Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17

Affimed to Enter into Co-Development Agreement with Genentech 18

Microbiotica Enters into Collaboration Agreement with Genentech 19

Tesaro Enters into Collaboration Agreement with Genentech 20

Lodo Therapeutics Enters into Agreement with Genentech 21

Tesaro Enters into Partnership with Genentech 22

Forty Seven Enters into Agreement with Genentech 23

Syndax Pharma Enters into Agreement with Genentech 24

DiCE Molecules Enters into Research Agreement with Genentech 25

Biothera Pharma Enters into Collaboration Agreement with Genentech 26

Epizyme Enters into Agreement with Genentech 27

Inovio Pharma Enters into Agreement with Genentech 28

Amunix Operating Enters into R&D Agreement with Genentech 29

BioNTech Enters into Agreement with Genentech 30

Gradalis Enters into Agreement with Genentech 31

G1 Therapeutics Enters into Agreement with Genentech 32

Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 33

Charles River Laboratories International Extends Agreement with Genentech 34

BioLineRx Enters into Agreement with Genentech 35

Epizyme Enters into Agreement with Genentech 36

Astex Pharma Enters into Agreement with Genentech 37

Clovis Oncology Enters into Agreement with Genentech 38

Janssen Research & Development Enters into Agreement with Genentech 39

Kite Pharma Enters into Agreement with Genentech 40

PeptiDream Enters into Agreement with Genentech 41

Corvus Pharma Expands its Agreement with Genentech 42

Immune Design Enters into Clinical Trial Collaboration with Genentech 43

WaferGen Bio-systems Enters into Research Agreement with Genentech 44

23andMe Partners with Genentech 45

Genentech Enters into Research Agreement with NewLink Genetics 46

Ascendis Pharma Enters Into Collaboration Agreement with Genentech 47

RQx Pharma Enters Into Drug Discovery Agreement With Genentech 48

Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 49

Constellation Pharma Enters into Co-Development Agreement With Genentech 50

Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 51

Genentech Enters into Licensing Agreement with Kineta Chronic Pain 52

Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 53

Mylan Enters into Licensing Agreement with Genentech and Roche 55

Genentech Enters into Licensing Agreement with Novimmune 56

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 57

Genentech to Enter into Licensing Agreement with Hanmi Pharma 58

Denali Therapeutics Enters Into Licensing Agreement With Genentech 59

Genentech Enters into Licensing Agreement with Nimbus Therapeutics 60

Genentech Expands Licensing Agreement with Arvinas 61

Genentech Enters into Licensing Agreement with Almac Discovery 62

Phylogica Extends Licensing Agreement with Genentech 63

Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 64

Coherus BioSciences Enters into Licensing Agreement with Genentech 66

Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 67

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 68

Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 69

Genentech Enters into Licensing Agreement with Carmot Therapeutics 70

Afraxis Enters Into Licensing Agreement With Genentech 71

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 72

Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 74

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 75

Genentech Inc, Key Competitors 76

Genentech Inc, Key Employees 77

Genentech Inc, Other Locations 78

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Genentech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including bio-oncology, immunology, ophthalmology, metabolism, primary care, neurology, virology, hematology and specialty care. It has pipeline candidates in oncology, immunology, neuroscience, metabolism, infectious disease and ophthalmology. The company has research and manufacturing facilities in Vacaville, South San Francisco and Oceanside, California. Genentech is headquartered in South San Francisco, California, the US.

Genentech Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13

Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Genentech Inc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17

Partnerships 18

Affimed to Enter into Co-Development Agreement with Genentech 18

Microbiotica Enters into Collaboration Agreement with Genentech 19

Tesaro Enters into Collaboration Agreement with Genentech 20

Lodo Therapeutics Enters into Agreement with Genentech 21

Tesaro Enters into Partnership with Genentech 22

Forty Seven Enters into Agreement with Genentech 23

Syndax Pharma Enters into Agreement with Genentech 24

DiCE Molecules Enters into Research Agreement with Genentech 25

Biothera Pharma Enters into Collaboration Agreement with Genentech 26

Epizyme Enters into Agreement with Genentech 27

Inovio Pharma Enters into Agreement with Genentech 28

Amunix Operating Enters into R&D Agreement with Genentech 29

BioNTech Enters into Agreement with Genentech 30

Gradalis Enters into Agreement with Genentech 31

G1 Therapeutics Enters into Agreement with Genentech 32

Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 33

Charles River Laboratories International Extends Agreement with Genentech 34

BioLineRx Enters into Agreement with Genentech 35

Epizyme Enters into Agreement with Genentech 36

Astex Pharma Enters into Agreement with Genentech 37

Clovis Oncology Enters into Agreement with Genentech 38

Janssen Research & Development Enters into Agreement with Genentech 39

Kite Pharma Enters into Agreement with Genentech 40

PeptiDream Enters into Agreement with Genentech 41

Corvus Pharma Expands its Agreement with Genentech 42

Immune Design Enters into Clinical Trial Collaboration with Genentech 43

WaferGen Bio-systems Enters into Research Agreement with Genentech 44

23andMe Partners with Genentech 45

Genentech Enters into Research Agreement with NewLink Genetics 46

Ascendis Pharma Enters Into Collaboration Agreement with Genentech 47

RQx Pharma Enters Into Drug Discovery Agreement With Genentech 48

Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 49

Constellation Pharma Enters into Co-Development Agreement With Genentech 50

Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 51

Licensing Agreements 52

Genentech Enters into Licensing Agreement with Kineta Chronic Pain 52

Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 53

Mylan Enters into Licensing Agreement with Genentech and Roche 55

Genentech Enters into Licensing Agreement with Novimmune 56

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 57

Genentech to Enter into Licensing Agreement with Hanmi Pharma 58

Denali Therapeutics Enters Into Licensing Agreement With Genentech 59

Genentech Enters into Licensing Agreement with Nimbus Therapeutics 60

Genentech Expands Licensing Agreement with Arvinas 61

Genentech Enters into Licensing Agreement with Almac Discovery 62

Phylogica Extends Licensing Agreement with Genentech 63

Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 64

Coherus BioSciences Enters into Licensing Agreement with Genentech 66

Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 67

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 68

Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 69

Genentech Enters into Licensing Agreement with Carmot Therapeutics 70

Afraxis Enters Into Licensing Agreement With Genentech 71

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 72

Acquisition 74

Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 74

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 75

Genentech Inc-Key Competitors 76

Genentech Inc-Key Employees 77

Genentech Inc-Locations And Subsidiaries 78

Head Office 78

Other Locations & Subsidiaries 78

Recent Developments 79

Legal and Regulatory 79

Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 79

Jan 09, 2017: Genentech withdraws counterclaim against Exelixis 80

Government and Public Interest 81

May 14, 2018: Pivotal Study Validates Real-World Mortality Endpoint for Oncology Research 81

Jun 29, 2017: Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury 82

Product News 83

Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 83

06/15/2017: NICE reverses provisional decision and recommends Kadcyla (trastuzumab emtansine) for HER2-positive advanced breast cancer in England 85

06/12/2017: T-DM1 in HER2 Overexpressing, Amplified or Mutated Metastatic NSCLC 86

Product Approvals 88

Jun 15, 2017: Kadcyla new deal for breast cancer patients given green light in final draft guidance 88

Apr 10, 2017: Roche's Kadcyla accepted for use in NHS Scotland 89

Clinical Trials 90

Apr 15, 2018: Genentech to Present Data on Investigational Anti-amyloid beta Antibodie Crenezumab 90

Dec 10, 2017: Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma 91

Nov 30, 2017: Symphogen Receives Milestone Payment for Initiation of Phase 1b Trial in Infectious Disease 93

Nov 01, 2017: Data To Be Presented On Polatuzumab Vedotin At ASH 2017 Annual Meeting 94

Oct 24, 2017: AC Immune to Provide Scientific Update on Crenezumab at CTAD Conference 95

May 17, 2017: Data from Clinical Study of NewLink Genetics' Navoximod to Be Presented at ASCO 2017 96

Apr 21, 2017: NewLink Genetics Provides Update on Pipeline Drug GDC-0919 at ASCO 97

Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab 98

Other Significant Developments 99

Feb 05, 2018: Inside Rx Provides Savings on Influenza Medications 99

Appendix 100

Methodology 100

About GlobalData 100

Contact Us 100

Disclaimer 100


List Of Figure

List of Figures

Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Genentech Inc, Pharmaceuticals & Healthcare, Key Facts 2

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Genentech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Genentech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Genentech Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Genentech Inc, Medical Devices Deals, 2012 to YTD 2018 13

Genentech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Genentech Acquires NanoPrint LM60 Microarrayer Platform From Arrayit 17

Affimed to Enter into Co-Development Agreement with Genentech 18

Microbiotica Enters into Collaboration Agreement with Genentech 19

Tesaro Enters into Collaboration Agreement with Genentech 20

Lodo Therapeutics Enters into Agreement with Genentech 21

Tesaro Enters into Partnership with Genentech 22

Forty Seven Enters into Agreement with Genentech 23

Syndax Pharma Enters into Agreement with Genentech 24

DiCE Molecules Enters into Research Agreement with Genentech 25

Biothera Pharma Enters into Collaboration Agreement with Genentech 26

Epizyme Enters into Agreement with Genentech 27

Inovio Pharma Enters into Agreement with Genentech 28

Amunix Operating Enters into R&D Agreement with Genentech 29

BioNTech Enters into Agreement with Genentech 30

Gradalis Enters into Agreement with Genentech 31

G1 Therapeutics Enters into Agreement with Genentech 32

Halozyme Therapeutics Enters into Clinical Trial Agreement with Genentech 33

Charles River Laboratories International Extends Agreement with Genentech 34

BioLineRx Enters into Agreement with Genentech 35

Epizyme Enters into Agreement with Genentech 36

Astex Pharma Enters into Agreement with Genentech 37

Clovis Oncology Enters into Agreement with Genentech 38

Janssen Research & Development Enters into Agreement with Genentech 39

Kite Pharma Enters into Agreement with Genentech 40

PeptiDream Enters into Agreement with Genentech 41

Corvus Pharma Expands its Agreement with Genentech 42

Immune Design Enters into Clinical Trial Collaboration with Genentech 43

WaferGen Bio-systems Enters into Research Agreement with Genentech 44

23andMe Partners with Genentech 45

Genentech Enters into Research Agreement with NewLink Genetics 46

Ascendis Pharma Enters Into Collaboration Agreement with Genentech 47

RQx Pharma Enters Into Drug Discovery Agreement With Genentech 48

Ensemble Therapeutics Enters Into Drug Discovery Agreement With Genentech 49

Constellation Pharma Enters into Co-Development Agreement With Genentech 50

Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 51

Genentech Enters into Licensing Agreement with Kineta Chronic Pain 52

Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 53

Mylan Enters into Licensing Agreement with Genentech and Roche 55

Genentech Enters into Licensing Agreement with Novimmune 56

Novogen Enters into Licensing Agreement with Genentech for GDC-0084 57

Genentech to Enter into Licensing Agreement with Hanmi Pharma 58

Denali Therapeutics Enters Into Licensing Agreement With Genentech 59

Genentech Enters into Licensing Agreement with Nimbus Therapeutics 60

Genentech Expands Licensing Agreement with Arvinas 61

Genentech Enters into Licensing Agreement with Almac Discovery 62

Phylogica Extends Licensing Agreement with Genentech 63

Genentech to Terminate Licensing Agreement with NewLink Genetics for NLG919 64

Coherus BioSciences Enters into Licensing Agreement with Genentech 66

Immunocore Enters Into Licensing And Research Agreement With Genentech For Cancer Drugs 67

Curis Enters Into Licensing Agreement With Genentech For IAP Inhibitor CUDC-427 68

Genentech Enters into Licensing Agreement with PeptiDream for PDPS Technology 69

Genentech Enters into Licensing Agreement with Carmot Therapeutics 70

Afraxis Enters Into Licensing Agreement With Genentech 71

AC Immune Enters Into Licensing Agreement With Genentech For Anti-Tau Antibodies 72

Noritsu Koki to Acquire 64.7% Stake in Genentech for USD27 Million 74

Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 75

Genentech Inc, Key Competitors 76

Genentech Inc, Key Employees 77

Genentech Inc, Other Locations 78

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Genentech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.